AbbVie Inc. (0QCV.L)
LSE - LSE Delayed price. Currency in EUR
Add to watchlist
At close: 12:39PM BST
| Previous close | 80.48 |
| Open | 104.39 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 104.39 - 104.39 |
| 52-week range | 104.39 - 104.39 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 133.665B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 30.77 |
| EPS (TTM) | 2.91 |
| Earnings date | 27 Apr 2023 - 01 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
Credit Suisse sees 96% plunge in equity trading revenue, plus other stocks on the move
Yahoo Finance Live’s Julie Hyman breaks down stock performance for Credit Suisse, AbbVie, and Kellogg.
- Yahoo Finance Video
America’s top-selling drug Humira loses monopoly status
Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss news that Abbvie’s Humira drug now faces competition.
- Business Wire
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
NORTH CHICAGO, Ill. & EXTON, Pa., January 06, 2023--AbbVie (NYSE: ABBV) and Immunome, Inc. (Nasdaq: IMNM), a clinical-stage biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, today announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery Engine.
© 2023 Yahoo. All rights reserved.
